BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 07:30 ET
|
ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 30, 2021 07:30 ET
|
ContraFect Corporation
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research...
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
March 11, 2021 16:05 ET
|
ContraFect Corporation
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...
PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network
October 06, 2020 16:02 ET
|
PRA Health Sciences, Inc.
With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health RALEIGH, N.C., Oct. 06, 2020 ...
Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform
June 10, 2020 09:00 ET
|
Cue Health Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today the close of its Series C financing round, raising $100 million in new capital....
RenovaCare Appoints Chief Medical Officer, Dr. Jo Ellen Schweinle, Former Sr. Medical Officer at U.S. Dept. of Health and Human Services
June 10, 2020 08:36 ET
|
RenovaCare, Inc.
ROSELAND, N.J., June 10, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment
May 28, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
RenovaCare Appoints Founding Director of BARDA Dr. Robin A. Robinson to Chief Scientific Officer
May 26, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
February 05, 2020 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...